Tuesday, February 3, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

Tesla’s Driverless Taxi Tests Ignite Investor Optimism

Robert Sasse by Robert Sasse
December 16, 2025
in Analysis, Automotive & E-Mobility, Nasdaq, Tech & Software, Trading & Momentum
0
Tesla Stock
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

A significant advancement in Tesla’s autonomous driving program is capturing market attention and fueling a substantial rally in the company’s shares. The catalyst is the confirmed commencement of fully driverless robotaxi testing on public roads in Austin, Texas, marking a pivotal transition in the technology’s development.

A Milestone in Autonomous Testing

For the first time, Tesla’s Model Y vehicles are operating on public streets without any human safety driver on board, a phase the company describes as “occupant-free.” CEO Elon Musk personally verified this development on his social media platform, X. This shift from supervised to unsupervised public testing represents a key milestone long anticipated by investors. Furthermore, it reinforces the projected timeline for Tesla’s “Cybercab” robotaxi concept, with volume production currently targeted for approximately April or May 2026.

Market Reaction and Technical Positioning

The news has been warmly received on the trading floor. Tesla’s stock recently closed at 404.35 euros, reflecting a gain of roughly 15% over the past month. From a charting perspective, the equity is trading decisively above its major moving averages. It currently holds a more than 30% premium above its 200-day line. The Relative Strength Index (RSI) reading of 73.7, however, indicates the shares have entered overbought territory following the recent surge.

Technical analysts, including Fundstrat’s Mark Newton, interpret the latest price action as a completed “roundtrip” move back to previous high zones, supported by strong trading volume. This confirms the prevailing upward trend, though the rapid pace may also invite some short-term profit-taking.

Key Market Data Points:
* Trend: Clear uptrend confirmed by technical breakout
* 12-Month Performance: Still slightly negative, but a strong recovery from the 52-week low is underway
* Volatility: Remains elevated at approximately 38% (30-day, annualized)

Should investors sell immediately? Or is it worth buying Tesla?

Fundamental Case Strengthened by Autonomy

On the fundamental side, progress in self-driving technology is providing a tailwind for analyst assessments. Prominent Tesla bull Dan Ives of Wedbush Securities maintains his “Outperform” rating and a $600 price target. His investment thesis increasingly centers on artificial intelligence and robotics, rather than traditional electric vehicle sales volume.

Ives envisions a scenario where Tesla could approach a $2 trillion market capitalization within the next twelve months. In a more optimistic case, he suggests a share price of up to $800 could be possible within the next 12 to 18 months. He emphasizes that this hinges on the market progressively valuing Tesla as a platform for autonomous mobility, dubbing the potential shift a “monster” catalyst for the year.

Tangible Progress Drives Sentiment Shift

The shift in market sentiment is driven by a concrete development: investors are now seeing real, occupant-free robotaxis navigating a major U.S. city, moving beyond mere promises. This tangible evidence supports the market view that Tesla’s full self-driving software stack has reached a mature enough technological state to allow for future scaling.

The current share price appears to factor in an expectation that the Austin tests will be expanded swiftly to other cities. The critical challenge for Tesla in coming quarters will be transitioning from this testing phase to a commercially viable robotaxi network and, ultimately, to the planned volume production in 2026. Success in this transition would likely see the autonomy business claim an ever-larger portion of the company’s overall valuation, gradually shifting the core focus away from conventional vehicle sales.

Ad

Tesla Stock: Buy or Sell?! New Tesla Analysis from February 3 delivers the answer:

The latest Tesla figures speak for themselves: Urgent action needed for Tesla investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from February 3.

Tesla: Buy or sell? Read more here...

Tags: Tesla
Robert Sasse

Robert Sasse

About Dr. Robert Sasse Accomplished economist, entrepreneur, and profound expert in financial markets. Dr. Robert Sasse holds a doctorate in economics and combines academic rigor with practical entrepreneurial experience. His deep expertise in economic relationships and unwavering conviction for a free-market liberal economic order drives his mission to provide investors with well-founded knowledge and guidance.
Areas of Expertise:
  • Economic Theory and Practice
  • Free-Market Economics
  • Entrepreneurship and Business Strategy
  • Investment Philosophy
Dr. Sasse's unique combination of academic knowledge and real-world business experience enables him to provide investors with comprehensive insights that bridge theory and practice.

Related Posts

Acadia Stock
Analysis

Setback in Europe Clouds Growth Outlook for Acadia

February 3, 2026
QuantumScape Stock
Analysis

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock
Analysis

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Next Post
Meta Stock

Meta Shares Under Pressure Following Critical Report

Oracle Stock

Oracle Shares Slump as Market Skepticism Overrides AI Partnership Denials

NASDAQ 100 Stock

Tech Stocks Lead Market Decline as Bond Yields Climb

Recommended

Biotechnology Trading online

Decline in Short Interest for Adobe NYSE ADBE Signals Bullish Sentiment

2 years ago
Cisco Stock

Cisco Stock Surges as Artificial Intelligence Drives Infrastructure Demand

3 months ago
Adaptive Biotechnologies Stock

Strategic Shift: Adaptive Biotechnologies Severs Major Pharma Alliance

6 months ago
Puma Stock

Puma Shares Face Critical Test Amid Mounting Challenges

4 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Q2 Holdings to Report Full-Year 2025 Financial Results

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

Commerce Bancshares Surpasses Market Forecasts in Year-End Report

Strategic Moves at Genworth Financial Ahead of Earnings

BancFirst Strengthens Regional Footprint with Acquisition Finalization

iShares MAFE ETF Reaches Fresh 52-Week Peak

Trending

Acadia Stock
Analysis

Setback in Europe Clouds Growth Outlook for Acadia

by Robert Sasse
February 3, 2026
0

Acadia Pharmaceuticals has encountered a significant obstacle for its European expansion strategy. Market uncertainty followed the announcement...

QuantumScape Stock

QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation

February 3, 2026
CNO Stock

CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

February 3, 2026
Q2 Holdings Stock

Q2 Holdings to Report Full-Year 2025 Financial Results

February 3, 2026
SpringWorks Therapeutics Stock

Merck KGaA’s Strategic Acquisition of SpringWorks Therapeutics Gains Momentum

February 3, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Setback in Europe Clouds Growth Outlook for Acadia
  • QuantumScape’s Pivotal Year: Scaling Up for Commercial Validation
  • CNO Financial Earnings Report: A Strategic Pivot Under the Microscope

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com